SCHEMBL5690454

SCHEMBL5690454

CC(Sc1ncc[nH]1)c1ccc(OC(=O)N2CCC(Oc3ccc(CC(=O)O)cc3)CC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.41
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MLNR O43193 3/20 0.37
F10 P00742 2/20 0.36
GPR119 Q8TDV5 3/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
RORC P51449 1/20 0.34
GAA P10253 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
PKM P14618 1/20 0.34
SLC5A7 Q9GZV3 1/20 0.34
F2 P00734 1/20 0.34
HRH3 Q9Y5N1 2/20 0.34
SRD5A1 P18405 1/20 0.34
NPY2R P49146 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5931723 0.89 GPR88 (0.39) GPR119NPY2R
SCHEMBL5688003 0.89 SRD5A1 (0.46) EPHX2MEN1KMT2AGPR119NPC1
SCHEMBL5690379 0.85 EPHX2 (0.44) EPHX2MLNRGPR119NPC1RAB9A
SCHEMBL5688297 0.84 ACACB (0.45) EPHX2GPR119NPC1RAB9AALDH1A1
SCHEMBL5688122 0.84 EPHX2 (0.42) EPHX2GPR119NPC1RAB9ALMNA
SCHEMBL5931457 0.83 LIPE (0.44) GPR119
SCHEMBL5715669 0.83 PANK3 (0.48) GPR119ALDH1A1LMNAHRH3
SCHEMBL5931736 0.82 EPHX2 (0.42) EPHX2MEN1KMT2AMLNRF10
SCHEMBL5931747 0.81 MGLL (0.38) NPC1RAB9AGAAALDH1A1NPY2R
SCHEMBL5691611 0.81 NPC1 (0.38) NPC1RAB9AGAAALDH1A1NPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC EPHX2 3290/4885MEN1 2729/4885KMT2A 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.